Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oritavancin - Melinta Therapeutics

Drug Profile

Oritavancin - Melinta Therapeutics

Alternative Names: LY-333328; LY-333328 diphosphate; Nuvocid; ORBACTIV; Oritavancin diphosphate; Ramvocid

Latest Information Update: 10 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer The Medicines Company
  • Class Antibacterials; Glycopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Skin and soft tissue infections
  • Phase II Bacteraemia
  • Phase I Gram-positive infections
  • Discontinued Anthrax; Clostridium difficile infections

Most Recent Events

  • 04 Sep 2019 Melinta Therapeutics completes a phase I trial in Skin and soft tissue infections in USA (IV) (NCT03873987)
  • 16 Jul 2019 Melinta Therapeutics initiates a phase I trial in Skin and soft tissue infections in USA (IV) (NCT03873987)
  • 18 Mar 2019 Melinta Therapeutics plans a phase I trial for a new formulation of oritavancin in Skin and soft tissue infections (IV) in July 2019 (NCT03873987)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top